# Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

> **NCT06976944** · PHASE2 · RECRUITING · sponsor: **Yukinori Ozaki** · enrollment: 44 (estimated)

## Conditions studied

- Recurrent Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06976944
- **Lead sponsor:** Yukinori Ozaki
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06976944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06976944, "Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06976944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*